Congratulations To

INNOGEN (Stock Code: 2591.HK)

On The Successful IPO On The Main board Of The HKEX!

COMPANY PROFILE

Guangzhou Innogen Pharmaceutical Group Co Ltd is a China-based investment holding company principally engaged in the research, development and commercialisation of pharmaceutical products. The Company is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The Company is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The Company principally conducts its businesses in the domestic market.

(Source：http://www.hkex.com.hk/）

CR SWCS Team is honoured to serve as INNOGEN’s Joint Company Secretary,

committed to ensuring governance, compliance, and sustained growth.